国际生殖健康/计划生育杂志

国际生殖健康/计划生育 ›› 2015, Vol. 34 ›› Issue (6): 491-494.

• 综述 • 上一篇    下一篇

HPV E6/E7研究现状及临床展望

鲁梦寒，李亚里   

  1. 100853 北京，中国人民解放军总医院妇产科
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2015-11-15 发布日期:2015-11-15

Research Progress and Clinical Application of Human Papillomavirus E6/E7

LU Meng-han，LI Ya-li   

  1. Department of Obstetrics and Gynecology，The PLA General Hospital，Beijing 100853，China
  • Received:1900-01-01 Revised:1900-01-01 Published:2015-11-15 Online:2015-11-15

PDF (PC)

7599

摘要： 人乳头状瘤病毒是宫颈癌最重要的致病因素，其早期蛋白E6/E7的持续表达可致细胞p53、pRb蛋白缺失或失活，并通过多种机制与其他细胞因子相互作用，促使细胞发生癌变。其mRNA表达水平提示病毒转录活性，可能具有诊断和预测宫颈病变的价值，因此有研究应用HPV E6/E7 mRNA筛查不同人群宫颈病变并随访、预测病变发生风险，但各研究结果不一，不同mRNA检测方法也是影响研究结果的因素之一。HPV E6/E7蛋白检测在临床应用较少，而以HPV E6/E7为靶点的宫颈癌免疫治疗已成为研究的热点，在动物实验及临床前研究中取得了一定进展。

关键词: 宫颈肿瘤, 宫颈疾病, 乳头状瘤病毒科, E6, E7

Abstract: The human papillomavirus (HPV) is a crucial causative agent of cervical cancer. The persistent expression of HPV E6/E7 protein degradates or inactivates p53 and pRb proteins, which induces the immortalization and malignant transformation of cells by interacting with multifarious cytokines and variable pathways. The level of E6/E7 mRNA indicates the transcription activity of HPV, suggesting that the E6/E7 mRNA can be used to diagnose cervical diseases. In some clinical practice, the level of HPV E6/E7 mRNA has been used in different population to screen and predict cervical lesions and to predict the risk of cervical diseases. However, there was not agreement at present in the clinical application. The difference in the methods to detect HPV E6/E7 mRNA may be one of causes of this disagreement. The HPV E6/E7 protein analysis was hardly used in clinical practice. The immunotherapy targeting the E6/E7 protein is a research hotspot, which has made some progress in animal experiment and preclinical study.

Key words: Uterine cervical neoplasms, Uterine cervical diseases, Papillomaviridae, E6, E7